Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-ranging study of SHR0302 in moderate to severe active Crohn's disease
2018-003303-19Phase 2Completed
- Sponsor
- Reistone Biopharma
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ivarmacitinib in Crohn's disease (4 arms), sponsored by Reistone Biopharma. Primary endpoint: Clinical remission at week 12 by CDAI. Started Jan 2019; status: completed.
02
Drugs
ivarmacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2018-003303-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003303-19.